PreprintReviewVersion 1This version is not peer-reviewed
Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public Perception
Version 1
: Received: 6 November 2024 / Approved: 7 November 2024 / Online: 7 November 2024 (16:30:23 CET)
How to cite:
Kusunoki, H. Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public Perception. Preprints2024, 2024110555. https://doi.org/10.20944/preprints202411.0555.v1
Kusunoki, H. Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public Perception. Preprints 2024, 2024110555. https://doi.org/10.20944/preprints202411.0555.v1
Kusunoki, H. Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public Perception. Preprints2024, 2024110555. https://doi.org/10.20944/preprints202411.0555.v1
APA Style
Kusunoki, H. (2024). Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public Perception. Preprints. https://doi.org/10.20944/preprints202411.0555.v1
Chicago/Turabian Style
Kusunoki, H. 2024 "Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public Perception" Preprints. https://doi.org/10.20944/preprints202411.0555.v1
Abstract
This report examines the evolving role of Coronavirus Disease 2019 (COVID-19) vaccination in Japan, especially in light of reduced public concern following the reclassification of COVID-19 as a Category 5 infectious disease in May 2023. With over half of the population estimated to have hybrid immunity from prior infections and vaccinations, this report evaluates the necessity and frequency of additional booster doses. Despite strong recommendations from Japanese medical societies to continue vaccinations, public skepticism remains due to financial burdens, adverse reactions, and the perceived limited benefit of frequent boosters. Studies of antibody responses reveal that individuals with hybrid immunity maintain robust protection, with significantly elevated antibody titers that persist over extended periods. Case studies indicate durable immunity among individuals who have both been vaccinated and experienced breakthrough infections, raising questions about the need for uniform booster policies. This report also discusses the newly approved replicon-type vaccines, currently available only in Japan, which have generated public and professional debate regarding their efficacy and safety.A more personalized approach to vaccination—taking into account antibody titers, prior infection history, and individual choice—is recommended. Ultimately, this report underscores the importance of aligning vaccination policies with scientific evidence and public sentiment to optimize COVID-19 countermeasures in Japan.
Keywords
COVID-19, vaccine
Subject
Medicine and Pharmacology, Internal Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
